The Asia Pacific peripheral liquid embolic agents market size was valued at USD 40.6 million in 2025 and is projected to grow from USD 44.8 million in 2026 to USD 91.1 million by 2036, at a CAGR of 7.4% from 2026 to 2036. The rising burden of peripheral artery disease and other vascular disorders across Asia Pacific is supporting demand for endovascular interventions. In addition, the growing adoption of minimally invasive vascular procedures is contributing to the use of catheter-based treatment approaches, particularly as healthcare systems emphasize procedures associated with lower procedural morbidity, shorter hospital stays, and faster patient recovery.
The rising burden of varicose veins in Asia Pacific is driving growth in the peripheral liquid embolic agent market, driven by growing demand for minimally invasive venous treatment approaches. Varicose veins, primarily associated with chronic venous insufficiency and malfunctioning venous valves, are becoming an important vascular health concern due to the aging population and increasing need for effective symptom management. The shift from conventional surgical vein stripping toward minimally invasive endovascular procedures has increased the adoption of advanced venous closure technologies. Liquid embolic agents, particularly adhesive-based embolic materials, are gaining attention for enabling non-thermal vein occlusion through controlled delivery and reduced dependence on energy-based ablation techniques. The rising number of patients undergoing treatment for symptomatic varicose veins, along with increasing physician preference for minimally invasive procedures, is creating opportunities for peripheral liquid embolic agents in venous applications.
For instance, data published by Springer in June 2026 and the 2024 National Clinical Database (NCD) annual report by the Japan Surgical Society indicate that 223,422 peripheral vascular surgical procedures were registered in the NCD in 2024, an increase of more than 2,700 cases compared with 2023. The procedure with the highest number in this category was endovascular treatment for extremity arteries.
The rising burden of varicose veins in Asia Pacific is driving growth in the peripheral liquid embolic agent market, driven by growing demand for minimally invasive venous treatment approaches. Varicose veins, primarily associated with chronic venous insufficiency and malfunctioning venous valves, are becoming an important vascular health concern due to the aging population and increasing need for effective symptom management. The shift from conventional surgical vein stripping toward minimally invasive endovascular procedures has increased the adoption of advanced venous closure technologies. Liquid embolic agents, particularly adhesive-based embolic materials, are gaining attention for enabling non-thermal vein occlusion through controlled delivery and reduced dependence on energy-based ablation techniques. The rising number of patients undergoing treatment for symptomatic varicose veins, along with increasing physician preference for minimally invasive procedures, is creating opportunities for peripheral liquid embolic agents in venous applications.
For instance, data published by Springer in June 2026 and the 2024 National Clinical Database (NCD) annual report by the Japan Surgical Society indicate that 223,422 peripheral vascular surgical procedures were registered in the NCD in 2024, an increase of more than 2,700 cases compared with 2023. The procedure with the highest number in this category was endovascular treatment for extremity arteries.
Asia Pacific Peripheral Liquid Embolic Agents Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, the analyst has segmented the Asia Pacific peripheral liquid embolic agents market report based on product type, application and end use:Product Type Outlook (Revenue, USD Million, 2021 - 2036)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates / tissue glues combined
- n-butyl cyanoacrylate (n-BCA)
- n-hexyl cyanoacrylate (n-HCA)
Application Outlook (Revenue, USD Million, 2021 - 2036)
- Peripheral Vascular Hemorrhage
- Hypervascular Tumors
- Peripheral Vascular Malformations / AVMs
- Aneurysms / Pseudoaneurysms
- Type II Endoleaks
- Portal Vein Embolization (PVE)
- Venous Applications (varicocele, PCS, varicose veins)
End Use Outlook (Revenue, USD Million, 2021 - 2036)
- Hospitals
- Others
Country Outlook (Revenue, USD Million, 2021-2036)
- Japan
- India
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Asia Pacific Peripheral Liquid Embolic Agents Market Variables, Trends, & Scope
Chapter 4. Asia Pacific Peripheral Liquid Embolic Agents Market: Product Type Estimates & Trend Analysis
Chapter 5. Asia Pacific Peripheral Liquid Embolic Agents Market: Application Estimates & Trend Analysis
Chapter 6. Asia Pacific Peripheral Liquid Embolic Agents Market: End Use Estimates & Trend Analysis
Chapter 7. Asia Pacific Peripheral Liquid Embolic Agents Market: Regional Estimates & Trend Analysis by Product Type, Application, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- BALT Group (via Getz Healthcare)
- GEM S.r.l. (H.B. Fuller Company)
- B. Braun SE
